Concepedia

J. Teng

JT

4

Publications

1.5K

Citations

4

H-Index

2007

Active since

Affiliations

Bristol-Myers Squibb (United States)(Current)

Bristol-Myers Squibb (Germany)

Hôpital Cochin

Stanford University

J. Teng is an author at Bristol-Myers Squibb (United States).

Publications per year

2007–2011

4

Publications

4

Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate

George A. Wells, J-C Becker, J. Teng et al. · Annals of the Rheumatic Diseases · 2008 · 836 citations · Full text

Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy

Mark C. Genovese, M. Schiff, Michael E. Luggen et al. · Annals of the Rheumatic Diseases · 2007 · 266 citations

Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexate

M. C. Genovese, A. Covarrubias, G. Léon et al. · Arthritis & Rheumatism · 2011 · 194 citations · Full text

Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial

H K Genant, Charles Peterfy, René Westhovens et al. · Annals of the Rheumatic Diseases · 2007 · 156 citations · Full text

Rows per page

1–4 of 4